Coverage
-
March 26, 2021
Novartis said its chairman incorrectly contradicted the company's admissions that it made as part of a $678 million deal with the federal government to settle claims it flouted the False Claims Act through a kickback scheme to pump up prescriptions.
7 other articles on this case.
View all »